Letrozole Cristers

Letrozole, the active ingredient in Letrozole Cristers, is an aromatase inhibitor presented as an oral formulation for oral use. It is employed in the endocrine treatment of postmenopausal women with estrogen receptor‑positive breast cancer, reducing estrogen production that can fuel tumor growth.

GNH USA supplies Letrozole Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple regions, and supporting clinical programs with consistent product availability through strategic partnerships.

Letrozole is an aromatase inhibitor used in the management of estrogen‑driven breast cancer across various disease stages. - Postmenopausal estrogen receptor‑positive breast cancer: reduces risk of recurrence when given as adjuvant therapy. - Advanced/metastatic estrogen receptor‑positive breast cancer: slows disease progression and prolongs survival. - Neoadjuvant treatment of ER‑positive tumors: facilitates tumor shrinkage prior to surgery.

Letrozole may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Hot flashes - Joint and muscle pain - Nausea - Fatigue

Serious or Rare Side Effects: - Severe liver dysfunction - Bone fracture due to decreased bone mineral density - Pulmonary embolism or other thromboembolic events

Before initiating therapy, clinicians should consider several safety measures. - Assess hepatic function: obtain baseline liver enzymes and monitor periodically. - Monitor bone health: evaluate bone mineral density and supplement calcium/vitamin D as needed. - Evaluate cardiovascular risk: check blood pressure and lipid profile regularly. - Avoid use in premenopausal women: Letrozole is not indicated for this population. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: antagonises Letrozole’s effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower Letrozole plasma levels.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin: may increase INR and bleeding risk. - Tamoxifen: potential pharmacodynamic interaction affecting hormonal pathways. - Selective serotonin reuptake inhibitors (e.g., paroxetine): may raise Letrozole concentrations.